ОбзорГрафикНовостиTraderScreen

HSBC Knock-Out REGN/  DE000HS1AVZ1  /

Frankfurt Zert./HSBC
07.11.2024  21:00:21 Изменение+0.120 Бид21:14:54 Предложение21:14:54 Базовый актив Цена исполнения Дата истечения Тип опциона
0.230EUR +109.09% 0.220
Величина цены спроса: 25,000		 0.230
Величина цены предложения: 25,000		 Regeneron Pharmaceut... 809.1814 USD 31.12.2078 Call
GlobeNewswire 28.08 Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
GlobeNewswire 26.08 Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...
GlobeNewswire 26.08 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire 21.08 Regeneron Provides Update on Biologics License Application for Linvoseltamab
GlobeNewswire 15.08 Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire 15.08 European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimi...
GlobeNewswire 12.08 Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...
GlobeNewswire 08.08 Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company ...
GlobeNewswire 07.08 Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
GlobeNewswire 05.08 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 01.08 Regeneron Reports Second Quarter 2024 Financial and Operating Results
GlobeNewswire 31.07 Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
GlobeNewswire 23.07 Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire 23.07 BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
GlobeNewswire 16.07 Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
GlobeNewswire 10.07 Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
GlobeNewswire 07.07 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 03.07 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...
GlobeNewswire 03.07 Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
GlobeNewswire 30.06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 28.06 Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...
GlobeNewswire 27.06 Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...
GlobeNewswire 26.06 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
GlobeNewswire 26.06 Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...
GlobeNewswire 22.06 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...